(PDF) Favorable Clinical Efficacy of Mepolizumab on the

Favorable Clinical Efficacy of Mepolizumab on the Upper and Lower Airways in Severe Eosinophilic Asthma: A 48-Week Pilot Study

European Annals of Allergy and Clinical Immunology - Italy

doi 10.23822/eurannaci.1764-1489.94

Full Text

Abstract

Available in full text

Categories

Date

September 1, 2019

Authors

Publisher

Edra SpA

Related search

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology

English

Mepolizumab for Severe Refractory Eosinophilic Asthma: Evidence to Date and Clinical Potential

Therapeutic Advances in Chronic Disease

English

Mepolizumab Improves Patient Outcomes and Reduces Exacerbations in Severe Asthma Patients With Comorbid Upper Airways Disease

Journal of Allergy and Clinical Immunology

English

Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice

Journal of Allergy and Clinical Immunology

English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics

English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology

English

Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France

Value in Health

Occupational Health

English

Efficacy of 100 Mg SC Mepolizumab for Severe Eosinophilic Asthma (SEA) Across Body Weight: Meta-Analysis

Journal of Allergy and Clinical Immunology

English

A Pilot Randomised Clinical Trial of Mepolizumab in COPD With Eosinophilic Bronchitis

European Respiratory Journal

Respiratory Medicine

English